BioNano Genomics (BNGO) Rating Reiterated by Roth Capital

Roth Capital restated their buy rating on shares of BioNano Genomics (NASDAQ:BNGO) in a research report released on Tuesday, February 5th.

Other equities analysts have also issued reports about the stock. ValuEngine upgraded shares of BioNano Genomics from a hold rating to a buy rating in a research report on Wednesday, November 7th. Zacks Investment Research lowered shares of BioNano Genomics from a hold rating to a sell rating in a research report on Wednesday, November 28th.

BNGO stock traded up $0.05 during midday trading on Tuesday, reaching $4.25. 29,967 shares of the company were exchanged, compared to its average volume of 7,933. The company has a debt-to-equity ratio of 0.59, a current ratio of 5.19 and a quick ratio of 4.72. BioNano Genomics has a 1-year low of $3.50 and a 1-year high of $10.00.

A number of large investors have recently bought and sold shares of the stock. Millennium Management LLC purchased a new position in BioNano Genomics in the 4th quarter valued at $254,000. Worth Venture Partners LLC lifted its holdings in BioNano Genomics by 1,666.6% in the fourth quarter. Worth Venture Partners LLC now owns 79,902 shares of the company’s stock valued at $417,000 after acquiring an additional 75,379 shares during the period. Monashee Investment Management LLC lifted its holdings in BioNano Genomics by 50.6% in the fourth quarter. Monashee Investment Management LLC now owns 245,860 shares of the company’s stock valued at $1,288,000 after acquiring an additional 82,595 shares during the period. Sio Capital Management LLC acquired a new stake in BioNano Genomics in the third quarter valued at $7,353,000. Finally, Federated Investors Inc. PA acquired a new stake in BioNano Genomics in the third quarter valued at $56,704,000. Hedge funds and other institutional investors own 82.57% of the company’s stock.

BioNano Genomics Company Profile

Bionano Genomics, Inc operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics.

See Also: Risk Tolerance and Your Investment Decisions

Receive News & Ratings for BioNano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply